• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JMIR Res Protoc . The Pregnancy Outcomes and Child Development Effects of SARS-CoV-2 Infection Study (PROUDEST): A Multicenter Prospective Cohort St

tetano

Editor, Senior Moderator
JMIR Res Protoc


. 2021 Feb 25.
doi: 10.2196/26477. Online ahead of print.
The Pregnancy Outcomes and Child Development Effects of SARS-CoV-2 Infection Study (PROUDEST): A Multicenter Prospective Cohort Study Protocol


Geraldo Magela Fernandes[SUP] 1 [/SUP], Felipe Motta[SUP] 1 [/SUP], Lizandra Moura Paravidine Sasaki[SUP] 1 [/SUP], ?ngelo Pereira Da Silva[SUP] 2 [/SUP], Andreza Monforte Miranda[SUP] 3 [/SUP], Aleida Oliveira De Carvalho[SUP] 2 [/SUP], Ana Paula Gomides Gomides[SUP] 4 [/SUP], Alexandre Anderson De Sousa Munhoz Soares[SUP] 1 [/SUP], Agenor De Castro Moreira Dos Santos Jr[SUP] 5 [/SUP], Caroline De Oliveira Alves[SUP] 1 [/SUP], Ciro Martins Gomes[SUP] 1 [/SUP], Clara Correia De Siracusa[SUP] 1 [/SUP], David Alves De Ara?jo Jr[SUP] 2 [/SUP], Dayde Lane Mendon?a Da Silva[SUP] 2 [/SUP], Jos? Alfredo Lacerda De Jesus[SUP] 1 [/SUP], Karina Nascimento Costa[SUP] 1 [/SUP], Maria Eduarda Canellas De Castro[SUP] 2 [/SUP], Patricia Shu Kurisky[SUP] 2 [/SUP], Paulo S?rgio Fran?a[SUP] 1 [/SUP], Rosana Maria Trist?o[SUP] 1 [/SUP], Yacara Ribeiro Pereira[SUP] 2 [/SUP], Luiz Claudio Gon?alves De Castro[SUP] 1 [/SUP], Alberto Moreno Zaconeta[SUP] 1 [/SUP], Cleandro Pires De Albuquerque[SUP] 2 [/SUP], Licia Maria Henrique Da Mota[SUP] 1 [/SUP]



Affiliations

Abstract

Background: A growing body of evidence suggests that infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) during pregnancy may affect maternal-fetal outcomes, with possible implications for the long-term development of exposed children.
Objective: The PRegnancy OUtcomes and child Development Effects of SARS-CoV-2 infection STudy (PROUDEST) is a multicenter prospective study designed to elucidate the repercussions of COVID-19 for mother-child global health.
Methods: The PROUDEST trial comprises two prospective sequential substudies. The PREGNANT substudy will assess the effects of SARS-CoV-2 infection on pregnancy, childbirth and puerperium clinically and from a mechanistic standpoint to elucidate the inflammatory and immunological phenomena underlying COVID-19 in relation to pregnancy. Pregnant women aged 18 to 40 years with laboratory-proven exposure to SARS-CoV-2 (group A, n = 300) will be compared to control subjects with no laboratory evidence of in-pregnancy exposure to the virus (group B, n = 300). Subjects exposed to other infections during pregnancy will be excluded. The BORN substudy is a long-term follow-up study assessing the offspring of women who entered the prior substudy. It will describe the effects of SARS-CoV-2 exposure during pregnancy on children's growth, neurodevelopment and metabolism from birth up to five years of age. It includes two comparison groups: group A (exposed, n = 300) comprises children born from SARS-CoV-2-exposed pregnancies, and group B (controls, n = 300) comprises children from nonexposed mothers.
Results: Recruitment began in July 2020, and as of September 2020, 115 pregnant women infected with SARS-CoV-2 during pregnancy and 80 newborns had been included. Data analysis is scheduled to start after all data have been collected.
Conclusions: Upon completion of the study, we expect to have obtained comprehensive data to provide a better understanding of the effects of SARS-CoV-2 and its inflammatory and immunological processes on pregnancy, puerperium and infancy. Our findings will inform clinical decisions regarding the care of exposed mothers and children and support the development of evidence-based public health policies.
Clinicaltrial: The PROUDEST study was registered on the Brazilian Register of Clinical Trials website (https://www. http://www.ensaiosclinicos.gov.br), ID RBR65QXS2, on June 13, 2020, where Brazilian clinical trials are exclusively registered.
 
Back
Top Bottom